Barclays has raised its price target for Eli Lilly to $1,400, citing momentum from tirzepatide. Other outlets have made various predictions about the stock's future price, with some suggesting it could reach as high as $1,800 by 2030, while others predict it will trade at $1,100 or $1,200. The stock has recently fallen 5% due to factors including an FDA decision and rivalry with Novo Nordisk.